Norovirus Research Reagents

VP1 (Major Capsid Protein) — VP1 comprises ~90% of virion protein mass and is highly variable across genogroups (GI, GII, GIV, GV, GVI) and genotypes. VP1 is the primary immunogenic antigen driving neutralizing antibody responses and vaccine protection. Recombinant VP1 antigens (VK441011) serve as ELISA coating antigens and vaccine immunogens. Recombinant antibodies (VK441073, VK441083, VK441113, VK441133) and nanobodies (VK441023, VK441043, VK441063) enable epitope mapping, neutralization assays, and therapeutic antibody discovery.
→ Browse VP1 products

VP2 (Minor Capsid Protein) — VP2 (~10% virion protein) stabilizes virion structure and participates in assembly. VP2-specific detection reagents support virion quality assessment and structural biology studies.
→ Browse VP2 products

Non-Structural Proteins — Protease and RdRp (NS1-NS7) are emerging targets for antiviral drug development and viral life cycle studies.

Seroprevalence & Epidemiology — VP1 ELISA assays enable population serosurveillance, outbreak investigation, and strain-specific immunity tracking.

Vaccine Development — Genogroup-specific VP1 antigens and neutralizing antibody quantification support potency testing and immunogenicity assessment.

Diagnostic Assay Development — VP1 antigens and paired recombinant antibodies enable sandwich ELISA, lateral flow, and molecular assay development.

Therapeutic Antibody Discovery — Broadly neutralizing antibodies (VK441133) enable passive immunization and post-exposure prophylaxis studies.

1. Siebenga JJ, et al. Norovirus illness is a global problem. J Infect Dis. 2009;200(6):802-812.

2. Patel MM, et al. Systematic review of noroviruses in sporadic gastroenteritis. Emerg Infect Dis. 2008;14(8):1224-1231.

3. Atmar RL, et al. Norovirus vaccine against experimental human infection. N Engl J Med. 2011;365(23):2178-2187.

4. Reeck A, et al. Serological evidence of frequent norovirus infections in childhood. J Clin Microbiol. 2010;48(12):4521-4526.

5. Lopman BA, et al. Prospects for vaccines against norovirus. Clin Infect Dis. 2018;67(9):1420-1428.